Brief: New Data Demonstrate Accuracy Of Veracyte's Whole-Genome Sequencing-Based Mrd Testing Platform For Muscle-Invasive Bladder Cancer
25/03/2025 20:07
March 25 (Reuters) - Veracyte Inc VCYT.O: NEW DATA DEMONSTRATE ACCURACY OF VERACYTE’S WHOLE-GENOME SEQUENCING-BASED MRD TESTING PLATFORM FOR MUSCLE-INVASIVE BLADDER CANCER VERACYTE INC - TO LAUNCH FIRST MRD TEST FOR MIBC IN H1 2026 Source text: ID:nBw89RxcKa Further company coverage: VCYT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Veracyte
See all newsU.S. STOCKS ON THE MOVE-Vor Biopharma, Fair Isaac Corp, Plug Power
U.S. STOCKS ON THE MOVE-Snowflake, Cboe, Oracle
US STOCKS ON THE MOVE-Veracyte, Staar Surgical, Corning
Veracyte gains on data supporting use of prostate cancer test to guide treatment decisions
Corrected: U.S. RESEARCH ROUNDUP-Abbvie, Amazon, Illumina